Remimazolam-based anesthesia to reduce delirium after laparoscopic gastrectomy in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, participant- and outcome-blinded trial comparing remimazolam-based anesthesia with propofol-midazolam-based anesthesia in elderly adults undergoing elective laparoscopic radical gastrectomy for gastric cancer. All participants receive standardized perioperative care with BIS-guided depth control and postoperative analgesia; delirium is assessed daily on postoperative days 1–3 using validated tools. Primary outcome is the cumulative incidence of postoperative delirium in the first three days; secondary outcomes include peri-induction blood pressure changes, hemodynamic variables, recovery metrics, pain scores, and adverse events. The trial randomized 147 participants 1:1, with allocation concealed and outcome assessors blinded to treatment. The study ran at The First Affiliated Hospital of Nanjing Medical University between January and August 2026.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 65 years.
* Body mass index (BMI) between 18 and 28 kg/m².
* ASA physical status I-III.
* Scheduled for elective laparoscopic radical gastrectomy under general anesthesia at Jiangsu Province Hospital.
* Able and willing to sign informed consent.

Exclusion Criteria:

* Severe respiratory, cardiovascular, renal, or hepatic dysfunction.
* Stroke within the past 6 months or other central nervous system diseases.
* History of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or other psychiatric disorders.
* History of alcohol abuse or psychoactive substance dependence.
* Severe visual, hearing, or language impairment preventing communication.
* Allergy or contraindication to propofol or benzodiazepines.
* Preoperative cognitive impairment assessed by MMSE (≤24 for ≥middle-school education; ≤20 for primary school; ≤17 for no formal education).
* Participation in another drug clinical trial within 1 month before surgery.

Where it's running

• The First Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Xiongxiong Pan
• Email: xiongxiong@njmu.edu.cn
• Phone: +86 13813801858

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Intranasal insulin to reduce delirium after heart surgery with a heart-lung machine

  This study tests whether giving intranasal insulin can reduce glycemic swings and delirium after elective heart surgery with cardiopulmonary bypass.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07893353

• Postoperative Pain Control in Elderly Knee Replacement

  This study tests two pain-management methods after knee replacement in adults 60 and older to see which one reduces delirium and improves recovery.

  Recruiting Ankara City Hospital Bilkent · Ankara, Çankaya · NCT07849517

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.